US 12,195,513 B2
LILRB1-based chimeric antigen receptor
Carl Alexander Kamb, Westlake Village, CA (US); Agnes E. Hamburger, Newbury Park, CA (US); Breanna Diandreth, Agoura Hills, CA (US); Mark E. Daris, Newbury Park, CA (US); and Kiran Deshmukh, Culver City, CA (US)
Assigned to A2 Biotherapeutics, Inc., Agoura Hills, CA (US)
Filed by A2 Biotherapeutics, Inc., Agoura Hills, CA (US)
Filed on Jan. 31, 2022, as Appl. No. 17/589,093.
Application 17/589,093 is a division of application No. 17/230,637, filed on Apr. 14, 2021, granted, now 11,254,726.
Application 17/230,637 is a continuation of application No. PCT/US2020/064607, filed on Dec. 11, 2020.
Claims priority of provisional application 63/085,969, filed on Sep. 30, 2020.
Claims priority of provisional application 62/946,888, filed on Dec. 11, 2019.
Prior Publication US 2022/0153807 A1, May 19, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/705 (2006.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01)
CPC C07K 14/70503 (2013.01) [A61K 35/17 (2013.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/2803 (2013.01); C07K 16/2833 (2013.01); C07K 16/3069 (2013.01); A61K 2039/505 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/03 (2013.01)] 18 Claims
 
1. A method of treating a subject with a disease or a disorder, comprising administering to the subject an immune cell comprising an inhibitory receptor comprising:
a) an antigen binding domain comprising a single chain variable fragment (scFv);
b) an LILRB1 hinge domain;
c) a transmembrane domain; and
d) an LILRB1 intracellular domain comprising at least one immunoreceptor tyrosine-based inhibitory motif (ITIM) selected from the group consisting of NLYAAV (SEQ ID NO: 8), VTYAEV (SEQ ID NO: 9), VTYAQL (SEQ ID NO: 10), and SIYATL (SEQ ID NO: 11),
wherein the LILRB1 hinge domain, transmembrane domain, and LILRB1 intracellular domain comprises a sequence at least 95% identical to SEQ ID NO: 2 or 3.